25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

EVOK (Evoke Pharma Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Evoke Pharma Inc together

I guess you are interested in Evoke Pharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Evoke Pharma Inc’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Evoke Pharma Inc’s Price Targets

I'm going to help you getting a better view of Evoke Pharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Evoke Pharma Inc

I send you an email if I find something interesting about Evoke Pharma Inc.

1. Quick Overview

1.1. Quick analysis of Evoke Pharma Inc (30 sec.)










1.2. What can you expect buying and holding a share of Evoke Pharma Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$2.29
Expected worth in 1 year
$2.24
How sure are you?
32.5%

+ What do you gain per year?

Total Gains per Share
$-0.05
Return On Investment
-1.9%

For what price can you sell your share?

Current Price per Share
$2.72
Expected price per share
$1.94 - $4.03
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Evoke Pharma Inc (5 min.)




Live pricePrice per Share (EOD)
$2.72
Intrinsic Value Per Share
$-14.56 - $9.09
Total Value Per Share
$-12.27 - $11.38

2.2. Growth of Evoke Pharma Inc (5 min.)




Is Evoke Pharma Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$5.8m$145.5k$4.8m97.1%

How much money is Evoke Pharma Inc making?

Current yearPrevious yearGrowGrow %
Making money-$1.2m-$1.7m$512.6k40.4%
Net Profit Margin-44.4%-120.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Evoke Pharma Inc (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Evoke Pharma Inc?

Welcome investor! Evoke Pharma Inc's management wants to use your money to grow the business. In return you get a share of Evoke Pharma Inc.

First you should know what it really means to hold a share of Evoke Pharma Inc. And how you can make/lose money.

Speculation

The Price per Share of Evoke Pharma Inc is $2.72. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Evoke Pharma Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Evoke Pharma Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.29. Based on the TTM, the Book Value Change Per Share is $-0.01 per quarter. Based on the YOY, the Book Value Change Per Share is $0.23 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Evoke Pharma Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.51-18.8%-0.76-27.9%-1.01-37.1%-1.03-37.9%-1.36-49.9%-1.48-54.6%
Usd Book Value Change Per Share-2.42-89.1%-0.01-0.5%0.238.4%0.083.1%0.020.6%-0.05-1.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-2.42-89.1%-0.01-0.5%0.238.4%0.083.1%0.020.6%-0.05-1.9%
Usd Price Per Share2.75-3.11-1.17-2.24-2.16-2.45-
Price to Earnings Ratio-1.34--1.06--0.30--0.61--0.48--0.51-
Price-to-Total Gains Ratio-1.14-1.13--2.11--0.74--1.08-2.10-
Price to Book Ratio1.20-1.01-0.28-0.72--0.43-0.27-
Price-to-Total Gains Ratio-1.14-1.13--2.11--0.74--1.08-2.10-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.72
Number of shares367
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.010.02
Usd Total Gains Per Share-0.010.02
Gains per Quarter (367 shares)-4.666.14
Gains per Year (367 shares)-18.6224.57
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-19-2902515
20-37-4804940
30-56-6707465
40-74-8609890
50-93-1050123115
60-112-1240147140
70-130-1430172165
80-149-1620197190
90-168-1810221215
100-186-2000246240

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.050.00.00.0%
Book Value Change Per Share2.02.00.050.0%4.08.00.033.3%5.015.00.025.0%13.027.00.032.5%16.034.00.032.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.050.00.0%
Total Gains per Share2.02.00.050.0%4.08.00.033.3%5.015.00.025.0%13.027.00.032.5%16.034.00.032.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Evoke Pharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---2.423-0.013-99%0.230-1155%0.083-3018%0.017-14573%-0.050-98%
Book Value Per Share--2.2922.933-22%0.337+581%2.147+7%1.909+20%2.308-1%
Current Ratio--1.5531.483+5%2.857-46%4.007-61%3.997-61%4.477-65%
Debt To Asset Ratio--0.6430.678-5%1.034-38%0.782-18%0.817-21%0.659-2%
Debt To Equity Ratio--1.8042.268-20%4.560-60%2.947-39%2.293-21%1.828-1%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--9098241.0006996799.435+30%146431.705+6113%4677100.913+95%4587433.363+98%6117643.019+49%
Eps---0.512-0.760+48%-1.010+97%-1.032+101%-1.358+165%-1.484+190%
Ev To Ebitda Ratio---1.923-1.534-20%-0.034-98%-0.819-57%-0.686-64%-0.778-60%
Ev To Sales Ratio--0.7380.585+26%0.036+1935%1.128-35%2.434-70%2.434-70%
Free Cash Flow Per Share---0.391-0.580+48%-0.891+128%-0.859+120%-1.154+195%-1.234+215%
Free Cash Flow To Equity Per Share---0.3820.557-169%0.350-209%0.736-152%0.567-167%0.291-231%
Gross Profit Margin--1.0001.0000%1.203-17%1.068-6%1.092-8%1.367-27%
Intrinsic Value_10Y_max--9.091----------
Intrinsic Value_10Y_min---14.561----------
Intrinsic Value_1Y_max---2.812----------
Intrinsic Value_1Y_min---4.372----------
Intrinsic Value_3Y_max---5.612----------
Intrinsic Value_3Y_min---10.691----------
Intrinsic Value_5Y_max---4.991----------
Intrinsic Value_5Y_min---14.282----------
Market Cap4060579.200-73%7008881.0005375764.685+30%2236309.205+213%3742842.413+87%3466491.713+102%3775612.694+86%
Net Profit Margin---0.424-0.444+5%-1.208+185%-1.592+275%-8.403+1882%-4.202+891%
Operating Margin----0.2200%-2.3900%-2.8060%-16.1170%-8.0580%
Operating Ratio--1.4231.437-1%2.149-34%2.502-43%9.049-84%4.524-69%
Pb Ratio1.187-1%1.2001.013+18%0.279+330%0.722+66%-0.430+136%0.271+343%
Pe Ratio-1.327+1%-1.341-1.058-21%-0.305-77%-0.606-55%-0.483-64%-0.511-62%
Price Per Share2.720-1%2.7503.115-12%1.173+135%2.237+23%2.160+27%2.448+12%
Price To Free Cash Flow Ratio-1.737+1%-1.757-1.374-22%-0.472-73%-0.811-54%-0.649-63%-0.588-67%
Price To Total Gains Ratio-1.123+1%-1.1351.133-200%-2.113+86%-0.741-35%-1.081-5%2.100-154%
Quick Ratio--1.4481.385+5%2.525-43%3.702-61%3.711-61%4.215-66%
Return On Assets---0.080-0.086+8%-0.208+161%-0.156+96%-0.205+157%-0.256+221%
Return On Equity---0.224-0.292+31%-0.980+338%-0.613+174%-0.504+125%-0.620+177%
Total Gains Per Share---2.423-0.013-99%0.230-1155%0.083-3018%0.017-14573%-0.050-98%
Usd Book Value--5841215.0004982829.750+17%145557.750+3913%3287354.833+78%2898794.750+102%3469746.200+68%
Usd Book Value Change Per Share---2.423-0.013-99%0.230-1155%0.083-3018%0.017-14573%-0.050-98%
Usd Book Value Per Share--2.2922.933-22%0.337+581%2.147+7%1.909+20%2.308-1%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--9098241.0006996799.435+30%146431.705+6113%4677100.913+95%4587433.363+98%6117643.019+49%
Usd Eps---0.512-0.760+48%-1.010+97%-1.032+101%-1.358+165%-1.484+190%
Usd Free Cash Flow---997509.000-969215.250-3%-1483368.000+49%-1368515.417+37%-1773413.550+78%-1867155.875+87%
Usd Free Cash Flow Per Share---0.391-0.580+48%-0.891+128%-0.859+120%-1.154+195%-1.234+215%
Usd Free Cash Flow To Equity Per Share---0.3820.557-169%0.350-209%0.736-152%0.567-167%0.291-231%
Usd Market Cap4060579.200-73%7008881.0005375764.685+30%2236309.205+213%3742842.413+87%3466491.713+102%3775612.694+86%
Usd Price Per Share2.720-1%2.7503.115-12%1.173+135%2.237+23%2.160+27%2.448+12%
Usd Profit---1306178.000-1269638.000-3%-1782261.250+36%-1722989.917+32%-2137553.150+64%-2270296.600+74%
Usd Revenue--3080158.0002898520.750+6%1526428.000+102%1716705.667+79%1132997.200+172%566498.600+444%
Usd Total Gains Per Share---2.423-0.013-99%0.230-1155%0.083-3018%0.017-14573%-0.050-98%
 EOD+3 -5MRQTTM+22 -14YOY+25 -123Y+23 -145Y+23 -1410Y+21 -16

3.3 Fundamental Score

Let's check the fundamental score of Evoke Pharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.327
Price to Book Ratio (EOD)Between0-11.187
Net Profit Margin (MRQ)Greater than0-0.424
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.448
Current Ratio (MRQ)Greater than11.553
Debt to Asset Ratio (MRQ)Less than10.643
Debt to Equity Ratio (MRQ)Less than11.804
Return on Equity (MRQ)Greater than0.15-0.224
Return on Assets (MRQ)Greater than0.05-0.080
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Evoke Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.432
Ma 20Greater thanMa 502.818
Ma 50Greater thanMa 1003.046
Ma 100Greater thanMa 2003.273
OpenGreater thanClose2.776
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Evoke Pharma Inc

Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is based in Solana Beach, California.

Fundamental data was last updated by Penke on 2025-06-19 05:18:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just not able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Evoke Pharma Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Evoke Pharma Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -42.4%Β means thatΒ $-0.42 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Evoke Pharma Inc:

  • The MRQ is -42.4%. The company is making a huge loss. -2
  • The TTM is -44.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-42.4%TTM-44.4%+2.0%
TTM-44.4%YOY-120.8%+76.4%
TTM-44.4%5Y-840.3%+795.9%
5Y-840.3%10Y-420.2%-420.2%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Evoke Pharma Inc is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Evoke Pharma Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • -8.0% Return on Assets means thatΒ Evoke Pharma Inc generatedΒ $-0.08 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Evoke Pharma Inc:

  • The MRQ is -8.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -8.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.0%TTM-8.6%+0.6%
TTM-8.6%YOY-20.8%+12.2%
TTM-8.6%5Y-20.5%+11.9%
5Y-20.5%10Y-25.6%+5.1%
4.3.1.3. Return on Equity

Shows how efficient Evoke Pharma Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Evoke Pharma Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • -22.4% Return on Equity means Evoke Pharma Inc generated $-0.22Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Evoke Pharma Inc:

  • The MRQ is -22.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -29.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-22.4%TTM-29.2%+6.8%
TTM-29.2%YOY-98.0%+68.8%
TTM-29.2%5Y-50.4%+21.2%
5Y-50.4%10Y-62.0%+11.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Evoke Pharma Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Evoke Pharma Inc is operatingΒ .

  • Measures how much profit Evoke Pharma Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Evoke Pharma Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Evoke Pharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-22.0%+22.0%
TTM-22.0%YOY-239.0%+217.0%
TTM-22.0%5Y-1,611.7%+1,589.7%
5Y-1,611.7%10Y-805.8%-805.8%
4.3.2.2. Operating Ratio

Measures how efficient Evoke Pharma Inc is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.42 means that the operating costs are $1.42 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Evoke Pharma Inc:

  • The MRQ is 1.423. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.437. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.423TTM1.437-0.014
TTM1.437YOY2.149-0.712
TTM1.4375Y9.049-7.612
5Y9.04910Y4.524+4.524
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Evoke Pharma Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Evoke Pharma Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.55Β means the company has $1.55 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Evoke Pharma Inc:

  • The MRQ is 1.553. The company is able to pay all its short-term debts. +1
  • The TTM is 1.483. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.553TTM1.483+0.070
TTM1.483YOY2.857-1.374
TTM1.4835Y3.997-2.514
5Y3.99710Y4.477-0.480
4.4.3.2. Quick Ratio

Measures if Evoke Pharma Inc is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Evoke Pharma Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.45Β means the company can pay off $1.45 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Evoke Pharma Inc:

  • The MRQ is 1.448. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 1.385. The company is able to pay all its short-term debts with the most liquid assets. +1
Trends
Current periodCompared to+/- 
MRQ1.448TTM1.385+0.063
TTM1.385YOY2.525-1.140
TTM1.3855Y3.711-2.326
5Y3.71110Y4.215-0.504
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Evoke Pharma Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Evoke Pharma IncΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Evoke Pharma Inc to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.64Β means that Evoke Pharma Inc assets areΒ financed with 64.3% credit (debt) and the remaining percentage (100% - 64.3%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Evoke Pharma Inc:

  • The MRQ is 0.643. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.678. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.643TTM0.678-0.035
TTM0.678YOY1.034-0.356
TTM0.6785Y0.817-0.139
5Y0.81710Y0.659+0.159
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Evoke Pharma Inc is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Evoke Pharma Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 180.4% means that company has $1.80 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Evoke Pharma Inc:

  • The MRQ is 1.804. The company is just able to pay all its debts with equity.
  • The TTM is 2.268. The company is just not able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.804TTM2.268-0.465
TTM2.268YOY4.560-2.292
TTM2.2685Y2.293-0.025
5Y2.29310Y1.828+0.465
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Evoke Pharma Inc generates.

  • Above 15 is considered overpriced butΒ always compareΒ Evoke Pharma Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -1.34 means the investor is paying $-1.34Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Evoke Pharma Inc:

  • The EOD is -1.327. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.341. Based on the earnings, the company is expensive. -2
  • The TTM is -1.058. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.327MRQ-1.341+0.015
MRQ-1.341TTM-1.058-0.283
TTM-1.058YOY-0.305-0.754
TTM-1.0585Y-0.483-0.576
5Y-0.48310Y-0.511+0.029
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Evoke Pharma Inc:

  • The EOD is -1.737. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.757. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.374. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.737MRQ-1.757+0.019
MRQ-1.757TTM-1.374-0.382
TTM-1.374YOY-0.472-0.903
TTM-1.3745Y-0.649-0.725
5Y-0.64910Y-0.588-0.061
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Evoke Pharma Inc is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 1.20 means the investor is paying $1.20Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Evoke Pharma Inc:

  • The EOD is 1.187. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.200. Based on the equity, the company is underpriced. +1
  • The TTM is 1.013. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.187MRQ1.200-0.013
MRQ1.200TTM1.013+0.187
TTM1.013YOY0.279+0.734
TTM1.0135Y-0.430+1.444
5Y-0.43010Y0.271-0.701
4.6.2. Total Gains per Share

2.4. Latest News of Evoke Pharma Inc

Does Evoke Pharma Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Evoke Pharma Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-06-18
09:32
Andrea Gisle Joosen appointed to Grafton Group boardRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Evoke Pharma Inc.

4.8.1. Institutions holding Evoke Pharma Inc

Institutions are holding 16.23% of the shares of Evoke Pharma Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Nantahala Capital Management, LLC9.92410.0162148153-41-0.0277
2025-03-31Bleichroeder LP4.60530.05046875000
2025-03-31Citadel Advisors Llc1.6614024803248030
2024-12-31UBS Group AG0.08430125811681297.7778
2025-03-31Tower Research Capital LLC0.014302132130
2025-03-31BlackRock Inc0.0082012200
2025-03-31SBI Securities Co Ltd0.00507500
2025-03-31Morgan Stanley - Brokerage Accounts0.004306433106.4516
2025-03-31Goss Wealth Management LLC0.001101700
2025-03-31Bank of America Corp0.00060900
2024-12-31AIGH Capital Management, LLC000-70546-100
2024-12-31Corsair Capital Management LLC000-11667-100
2024-12-31Northern Trust Investments N A000-292-100
2024-12-31Citigroup Inc000-4-100
Total 16.30860.0666243464-56333-23.1%

4.9.2. Funds holding Evoke Pharma Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-04-30Fidelity Extended Market Index0.4290.0001640500
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr0.16660248700
2025-04-30Fidelity Series Total Market Index0.09920148100
2025-03-31Northern Trust Extended Eq Market Idx0.0113016800
2025-03-31NT Ext Equity Mkt Idx Fd - L0.0113016800
2025-03-31NT Ext Equity Mkt Idx Fd - NL0.0068010100
2025-03-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.0053079-1-1.25
2025-04-30Spartan Total Market Index Pool G0.004707000
2025-05-31State St US Extended Mkt Indx NL Cl C0.003605400
2025-03-31BNYM Mellon SL Market Completion UC10.003104600
2025-04-30Fidelity Total Market Index0.002704100
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T30.0027040400
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T40.0027040400
2025-03-31NT Ext Eq Mkt Indx Fd DC Lending Tier 50.002704000
2025-03-31SSgA U.S. Total Market Index Strategy0.001502300
2025-03-31Northern Trust Wilshire 50000.001301900
Total 0.75450.000111262+79+0.7%

5.3. Insider Transactions

Insiders are holding 1.336% of the shares of Evoke Pharma Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-01-28Nantahala Capital Management,SELL414.39
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets16,376
Total Liabilities10,535
Total Stockholder Equity5,841
 As reported
Total Liabilities 10,535
Total Stockholder Equity+ 5,841
Total Assets = 16,376

Assets

Total Assets16,376
Total Current Assets16,231
Long-term Assets145
Total Current Assets
Cash And Cash Equivalents 12,624
Net Receivables 2,511
Inventory 532
Other Current Assets 563
Total Current Assets  (as reported)16,231
Total Current Assets  (calculated)16,231
+/-0
Long-term Assets
Property Plant Equipment 139
Long-term Assets Other 6
Long-term Assets  (as reported)145
Long-term Assets  (calculated)145
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities10,452
Long-term Liabilities83
Total Stockholder Equity5,841
Total Current Liabilities
Short-term Debt 62
Short Long Term Debt 5,000
Accounts payable 2,781
Other Current Liabilities 10,390
Total Current Liabilities  (as reported)10,452
Total Current Liabilities  (calculated)18,233
+/- 7,781
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt83
Long-term Liabilities  (as reported)83
Long-term Liabilities  (calculated)83
+/-0
Total Stockholder Equity
Common Stock0
Retained Earnings -130,098
Other Stockholders Equity 135,939
Total Stockholder Equity (as reported)5,841
Total Stockholder Equity (calculated)5,841
+/-0
Other
Capital Stock0
Cash and Short Term Investments 12,624
Common Stock Shares Outstanding 2,549
Liabilities and Stockholders Equity 16,376
Net Debt -12,479
Net Invested Capital 10,841
Net Working Capital 5,779
Property Plant and Equipment Gross 139
Short Long Term Debt Total 145



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-31
> Total Assets 
905
0
0
0
116
1,680
1,793
23,738
24,986
22,567
17,023
13,391
15,302
12,621
10,608
11,683
9,532
6,872
4,636
10,813
9,294
14,838
13,156
10,759
7,942
5,585
6,626
7,018
5,660
4,363
7,631
7,327
6,396
4,638
8,267
6,751
9,434
19,296
17,557
11,650
10,573
9,026
14,404
13,411
11,851
10,039
8,980
7,853
7,069
12,454
12,136
14,154
17,519
16,376
16,37617,51914,15412,13612,4547,0697,8538,98010,03911,85113,41114,4049,02610,57311,65017,55719,2969,4346,7518,2674,6386,3967,3277,6314,3635,6607,0186,6265,5857,94210,75913,15614,8389,29410,8134,6366,8729,53211,68310,60812,62115,30213,39117,02322,56724,98623,7381,7931,680116000905
   > Total Current Assets 
0
0
0
0
116
1,670
1,050
23,738
24,431
22,012
16,935
13,308
15,249
12,574
10,608
11,675
9,524
6,872
4,636
10,813
9,283
14,827
13,144
10,748
7,930
5,585
6,626
7,007
5,648
4,260
7,561
7,292
6,246
4,533
8,196
6,715
9,281
19,176
17,472
11,601
10,561
9,026
14,404
13,257
11,722
9,948
8,927
7,840
6,827
12,454
12,136
14,038
17,238
16,231
16,23117,23814,03812,13612,4546,8277,8408,9279,94811,72213,25714,4049,02610,56111,60117,47219,1769,2816,7158,1964,5336,2467,2927,5614,2605,6487,0076,6265,5857,93010,74813,14414,8279,28310,8134,6366,8729,52411,67510,60812,57415,24913,30816,93522,01224,43123,7381,0501,6701160000
       Cash And Cash Equivalents 
866
0
0
0
116
1,670
1,050
23,738
24,197
21,835
16,046
12,177
14,156
11,692
9,883
10,739
8,691
6,100
4,129
10,380
9,007
14,655
12,556
10,413
7,679
5,406
6,531
6,568
5,319
4,029
7,440
6,505
5,664
4,133
7,990
6,281
8,069
18,186
16,721
11,142
9,145
7,701
13,451
12,350
9,844
8,213
7,006
5,965
4,739
9,703
9,178
11,339
13,597
12,624
12,62413,59711,3399,1789,7034,7395,9657,0068,2139,84412,35013,4517,7019,14511,14216,72118,1868,0696,2817,9904,1335,6646,5057,4404,0295,3196,5686,5315,4067,67910,41312,55614,6559,00710,3804,1296,1008,69110,7399,88311,69214,15612,17716,04621,83524,19723,7381,0501,670116000866
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
336
23
128
198
222
295
419
366
675
625
687
1,024
1,234
673
1,452
2,003
2,023
2,420
2,511
2,5112,4202,0232,0031,4526731,2341,0246876256753664192952221981282333600000000000000000000000000000000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
86
236
236
234
225
186
279
268
220
289
365
514
505
482
589
545
493
445
532
5324454935455894825055143652892202682791862252342362368600000000000000000000000000000000000
   > Long-term Assets 
0
0
0
0
0
11
743
0
556
556
88
83
53
47
0
8
8
8
0
0
12
12
12
12
12
12
0
12
12
103
70
35
150
105
71
36
153
120
85
49
12
0
0
154
129
91
53
13
242
242
0
115
281
145
14528111502422421353911291540012498512015336711051503570103121201212121212120088804753838855655607431100000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
103
70
35
139
105
71
36
142
120
85
49
12
0
0
154
129
91
53
13
0
0
0
0
154
139
1391540000135391129154001249851201423671105139357010300000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
743
0
555
556
88
83
53
47
0
8
8
0
0
0
11
11
12
11
12
0
0
12
12
0
0
0
12
0
0
0
153,256
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000153,256000120001212001211121111000880475383885565550743000000
> Total Liabilities 
335
0
0
0
19,775
21,830
3,729
4,515
3,803
4,116
1,854
1,700
6,113
6,188
6,296
6,375
6,067
6,115
6,163
6,110
5,507
6,904
6,386
8,700
5,776
1,196
1,266
1,611
1,634
1,287
1,285
2,154
2,015
1,716
8,641
8,674
12,649
11,485
11,592
6,877
7,018
7,092
7,213
7,878
7,767
7,913
8,441
8,727
9,648
8,957
9,471
9,766
10,481
10,535
10,53510,4819,7669,4718,9579,6488,7278,4417,9137,7677,8787,2137,0927,0186,87711,59211,48512,6498,6748,6411,7162,0152,1541,2851,2871,6341,6111,2661,1965,7768,7006,3866,9045,5076,1106,1636,1156,0676,3756,2966,1886,1131,7001,8544,1163,8034,5153,72921,83019,775000335
   > Total Current Liabilities 
335
0
0
0
570
668
1,488
2,637
2,285
2,944
1,837
1,685
1,872
2,500
3,194
2,006
1,834
2,434
6,163
1,012
1,412
1,136
1,879
2,649
2,075
1,196
1,266
1,611
1,634
1,287
1,285
2,154
2,015
1,716
6,641
6,621
7,536
6,249
6,231
1,390
1,406
1,357
1,353
1,878
1,655
1,678
2,081
2,240
3,036
8,957
9,471
9,766
10,380
10,452
10,45210,3809,7669,4718,9573,0362,2402,0811,6781,6551,8781,3531,3571,4061,3906,2316,2497,5366,6216,6411,7162,0152,1541,2851,2871,6341,6111,2661,1962,0752,6491,8791,1361,4121,0126,1632,4341,8342,0063,1942,5001,8721,6851,8372,9442,2852,6371,488668570000335
       Short-term Debt 
0
0
0
0
0
0
701
1,070
1,443
1,443
0
0
150
713
1,252
0
146
709
4,400
0
146
0
0
0
0
0
0
0
0
207
140
71
277
211
175
140
246
240
170
98
25
0
0
281
258
183
106
27
5,000
5,000
5,000
5,000
5,060
62
625,0605,0005,0005,0005,00027106183258281002598170240246140175211277711402070000000014604,40070914601,252713150001,4431,4431,070701000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
127
0
0
0
146
0
0
0
0
0
0
0
0
0
0
0
0
103
0
0
0
0
104
104
104
0
0
0
0
0
0
0
0
0
0
0
5,000
5,000
5,000
5,000
5,000
5,000
5,0005,0005,0005,0005,0005,000000000000001041041040000103000000000000146000127000000000000
       Accounts payable 
89
0
0
0
97
0
601
1,176
285
1,116
1,300
1,049
990
1,353
1,373
1,338
928
1,243
1,264
498
478
549
1,122
1,721
1,049
546
441
626
476
492
408
1,155
1,033
926
605
766
1,274
691
519
531
874
944
824
1,021
868
1,186
1,415
1,397
1,712
1,640
1,900
2,188
2,341
2,781
2,7812,3412,1881,9001,6401,7121,3971,4151,1868681,0218249448745315196911,2747666059261,0331,1554084924766264415461,0491,7211,1225494784981,2641,2439281,3381,3731,3539901,0491,3001,1162851,17660109700089
       Other Current Liabilities 
246
0
0
0
570
668
1,012
391
557
385
537
636
732
434
570
669
761
483
499
514
933
587
757
928
1,026
650
825
985
1,158
589
738
929
705
580
5,861
5,715
6,016
5,318
5,543
762
507
412
529
577
528
309
560
816
1,324
2,317
2,571
3,975
2,979
10,390
10,3902,9793,9752,5712,3171,3248165603095285775294125077625,5435,3186,0165,7155,8615807059297385891,1589858256501,0269287575879335144994837616695704347326365373855573911,012668570000246
   > Long-term Liabilities 
0
0
0
0
19,205
21,162
2,241
1,878
1,518
1,172
17
15
4,241
3,688
3,102
4,369
4,233
3,681
0
5,098
4,095
5,769
4,507
6,051
3,701
3,701
0
0
0
0
0
0
0
0
2,000
2,053
5,113
5,236
5,360
5,486
5,612
5,736
5,860
6,000
6,112
6,236
6,360
6,486
6,612
6,737
0
0
101
83
83101006,7376,6126,4866,3606,2366,1126,0005,8605,7365,6125,4865,3605,2365,1132,0532,000000000003,7013,7016,0514,5075,7694,0955,09803,6814,2334,3693,1023,6884,24115171,1721,5181,8782,24121,16219,2050000
       Long term Debt Total 
0
0
0
0
0
0
0
1,878
1,511
1,157
0
0
4,241
3,688
3,102
4,369
4,233
3,681
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,000
2,000
5,000
5,000
5,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000005,0005,0005,0002,0002,00000000000000000003,6814,2334,3693,1023,6884,241001,1571,5111,8780000000
       Other Liabilities 
0
0
0
0
0
0
0
0
7
16
17
15
0
0
0
0
0
0
0
5,098
4,095
5,768
4,507
6,050
3,701
0
0
0
0
0
0
0
0
0
0
53
113
236
360
486
612
736
860
986
1,112
1,236
1,360
0
0
0
0
0
0
0
00000001,3601,2361,1129868607366124863602361135300000000003,7016,0504,5075,7684,0955,0980000000151716700000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
7
16
17
15
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000151716700000000
> Total Stockholder Equity
570
0
0
0
-19,659
-20,150
-1,936
19,223
21,183
18,451
15,169
11,691
9,189
6,433
4,312
5,308
3,465
757
-1,527
4,703
3,788
7,934
6,770
2,060
2,166
4,389
5,360
5,408
4,025
3,075
6,346
5,173
4,381
2,922
-374
-1,923
-3,215
7,811
5,966
4,773
3,555
1,934
7,191
5,533
4,085
2,126
538
-874
-2,580
3,497
2,665
4,387
7,038
5,841
5,8417,0384,3872,6653,497-2,580-8745382,1264,0855,5337,1911,9343,5554,7735,9667,811-3,215-1,923-3742,9224,3815,1736,3463,0754,0255,4085,3604,3892,1662,0606,7707,9343,7884,703-1,5277573,4655,3084,3126,4339,18911,69115,16918,45121,18319,223-1,936-20,150-19,659000570
   Common Stock
0
0
0
0
0
1
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
0
0
0
0
0
0
0
1
0
0
0
0
000010000000333333332222222222222111111111111110100000
   Retained Earnings Total Equity000000000000000-103,781-101,491-98,885-96,617-94,488-87,521-85,730-84,312-82,684-80,570-78,605-76,844-75,325-73,021-71,039-70,730-65,487-63,861-58,809-57,282-54,257-51,286-48,061-45,436-42,701-39,460-35,939-33,019-29,194-25,647-22,691-21,0750000000
   Accumulated Other Comprehensive Income 0000000000000000000000000000000000000000000000-23,738,053-18,2250-18,2250000
   Capital Surplus 
0
0
0
0
0
0
0
40,297
43,874
44,097
44,363
44,709
45,127
45,893
47,012
50,743
51,525
52,042
52,729
61,984
62,596
71,793
72,256
72,788
73,203
77,409
80,683
82,250
82,628
83,644
89,028
89,483
90,108
90,440
94,112
94,691
95,668
109,299
109,744
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000109,744109,29995,66894,69194,11290,44090,10889,48389,02883,64482,62882,25080,68377,40973,20372,78872,25671,79362,59661,98452,72952,04251,52550,74347,01245,89345,12744,70944,36344,09743,87440,2970000000
   Treasury Stock000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
-18,030
18,424
36,878
23,778,350
43,874
44,097
44,363
44,709
45,127
45,893
47,012
50,743
51,525
52,042
52,729
61,984
62,596
71,793
72,256
72,788
73,203
77,409
80,683
82,250
82,628
83,644
89,028
89,483
90,108
90,440
94,112
94,691
95,668
109,299
109,744
110,521
110,975
111,527
119,021
119,376
119,731
120,016
120,296
120,578
120,860
128,516
128,951
131,986
135,829
135,939
135,939135,829131,986128,951128,516120,860120,578120,296120,016119,731119,376119,021111,527110,975110,521109,744109,29995,66894,69194,11290,44090,10889,48389,02883,64482,62882,25080,68377,40973,20372,78872,25671,79362,59661,98452,72952,04251,52550,74347,01245,89345,12744,70944,36344,09743,87423,778,35036,87818,424-18,0300000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue10,249
Cost of Revenue-357
Gross Profit9,8939,893
 
Operating Income (+$)
Gross Profit9,893
Operating Expense-15,097
Operating Income-5,204-5,204
 
Operating Expense (+$)
Research Development16
Selling General Administrative15,081
Selling And Marketing Expenses0
Operating Expense15,09715,097
 
Net Interest Income (+$)
Interest Income353
Interest Expense-501
Other Finance Cost-0
Net Interest Income-148
 
Pretax Income (+$)
Operating Income-5,204
Net Interest Income-148
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-5,352-5,056
EBIT - interestExpense = -501
-5,352
-4,851
Interest Expense501
Earnings Before Interest and Taxes (EBIT)0-4,851
Earnings Before Interest and Taxes (EBITDA)-4,851
 
After tax Income (+$)
Income Before Tax-5,352
Tax Provision-0
Net Income From Continuing Ops-5,352-5,352
Net Income-5,352
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses15,454
Total Other Income/Expenses Net-148148
 

Technical Analysis of Evoke Pharma Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Evoke Pharma Inc. The general trend of Evoke Pharma Inc is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Evoke Pharma Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Evoke Pharma Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Evoke Pharma Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.92 < 4.02 < 4.03.

The bearish price targets are: 2.46 > 1.94.

Know someone who trades $EVOK? Share this with them.πŸ‘‡

Evoke Pharma Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Evoke Pharma Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Evoke Pharma Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Evoke Pharma Inc. The current macd is -0.13666059.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Evoke Pharma Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Evoke Pharma Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Evoke Pharma Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Evoke Pharma Inc Daily Moving Average Convergence/Divergence (MACD) ChartEvoke Pharma Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Evoke Pharma Inc. The current adx is 30.77.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Evoke Pharma Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Evoke Pharma Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Evoke Pharma Inc. The current sar is 2.46.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Evoke Pharma Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Evoke Pharma Inc. The current rsi is 43.43. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Evoke Pharma Inc Daily Relative Strength Index (RSI) ChartEvoke Pharma Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Evoke Pharma Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Evoke Pharma Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Evoke Pharma Inc Daily Stochastic Oscillator ChartEvoke Pharma Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Evoke Pharma Inc. The current cci is -28.23747405.

Evoke Pharma Inc Daily Commodity Channel Index (CCI) ChartEvoke Pharma Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Evoke Pharma Inc. The current cmo is -11.21602563.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Evoke Pharma Inc Daily Chande Momentum Oscillator (CMO) ChartEvoke Pharma Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Evoke Pharma Inc. The current willr is -52.52875662.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Evoke Pharma Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Evoke Pharma Inc Daily Williams %R ChartEvoke Pharma Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Evoke Pharma Inc.

Evoke Pharma Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Evoke Pharma Inc. The current atr is 0.2199309.

Evoke Pharma Inc Daily Average True Range (ATR) ChartEvoke Pharma Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Evoke Pharma Inc. The current obv is 17,609,509.

Evoke Pharma Inc Daily On-Balance Volume (OBV) ChartEvoke Pharma Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Evoke Pharma Inc. The current mfi is 35.28.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Evoke Pharma Inc Daily Money Flow Index (MFI) ChartEvoke Pharma Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Evoke Pharma Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-18STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-02-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-02-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-04RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-10WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-17STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-20STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-27STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-21RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-04-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-24CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-01BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-05MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-09STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-12WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-05-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-21STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-22BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-06-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-23STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-06-26STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.

6.3. Candlestick Patterns

Evoke Pharma Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Evoke Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.432
Ma 20Greater thanMa 502.818
Ma 50Greater thanMa 1003.046
Ma 100Greater thanMa 2003.273
OpenGreater thanClose2.776
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Evoke Pharma Inc with someone you think should read this too:
  • Are you bullish or bearish on Evoke Pharma Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Evoke Pharma Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Evoke Pharma Inc

I send you an email if I find something interesting about Evoke Pharma Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Evoke Pharma Inc.

Receive notifications about Evoke Pharma Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.